Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial

INTRODUCTION: Finding therapeutic alternatives to carbapenems in infections caused by extended-spectrum β-lactamase-producing Escherichia coli (ESBL-EC) is imperative. Although fosfomycin was discovered more than 40 years ago, it was not investigated in accordance with current standards and so is no...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosso-Fernández, Clara, Sojo-Dorado, Jesús, Barriga, Angel, Lavín-Alconero, Lucía, Palacios, Zaira, López-Hernández, Inmaculada, Merino, Vicente, Camean, Manuel, Pascual, Alvaro, Rodríguez-Baño, Jesús
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Infectious Diseases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4386243/
https://www.ncbi.nlm.nih.gov/pubmed/25829373
http://dx.doi.org/10.1136/bmjopen-2014-007363

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4386243/
https://www.ncbi.nlm.nih.gov/pubmed/25829373
http://dx.doi.org/10.1136/bmjopen-2014-007363

Ejemplares similares